Logotype for Novolog (Pharm-Up 1966) Ltd

Novolog (NVLG) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Novolog (Pharm-Up 1966) Ltd

Q4 2025 earnings summary

23 Mar, 2026

Executive summary

  • Revenue for 2025 was reported between ₪1,643.5 million and ₪1,805.4 million, reflecting a year-over-year decrease.

  • Net income for 2025 ranged from a net loss of ₪39.4 million to a net profit of ₪4.5 million, with significant operational challenges from SAP ERP implementation and related class action lawsuit.

  • Adjusted EBITDA for 2025 was between ₪97.2 million and ₪128.8 million, down year-over-year.

  • Strategic focus on operational efficiency, technology, innovation, and divestment of non-core assets, including the sale of Nuvhalet and full acquisition of Pronto.

  • Q4 2025 saw a net loss, impacted by one-time losses from subsidiary sale, legal provisions, and SAP-related disruptions.

Financial highlights

  • Gross profit for 2025 ranged from ₪137.5 million to ₪180.8 million, with gross margin between 7.6% and 10.9%.

  • Operating profit for 2025 was ₪24.1 million, with an operating margin of 1.5%.

  • Cash balance at year-end was ₪121.7 million; cash flow from operations was ₪158.5 million.

  • Equity at year-end stood between ₪369 million and ₪382.1 million.

  • Dividend distributions in 2025 totaled ₪20 million, with a payout policy of 70% of net profit.

Outlook and guidance

  • No additional financing anticipated for 2026; focus on organic growth, selective acquisitions, and contingency planning for geopolitical and macroeconomic risks.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more